Author Correction: Liposomal delivery of azithromycin enhances its immunotherapeutic efficacy and reduces toxicity in myocardial infarction

Documenti analoghi

• Liposomal delivery of azithromycin enhances its immunotherapeutic efficacy and reduces toxicity in myocardial infarction
  di: Al-Darraji, Ahmed, et al.
  Pubblicazione: (2020)
• Azithromycin therapy reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction: Potential therapeutic targets in ischemic heart disease
  di: Al-Darraji, Ahmed, et al.
  Pubblicazione: (2018)
• Autotaxin Inhibition Reduces Cardiac Inflammation and Mitigates Adverse Cardiac Remodeling After Myocardial Infarction
  di: Tripathi, Himi, et al.
  Pubblicazione: (2020)
• Isolation Methods for Human CD34 subsets Using Fluorescent and Magnetic Activated Cell Sorting: an In Vivo Comparative Study
  di: Tripathi, Himi, et al.
  Pubblicazione: (2020)
• Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19
  di: Venditto, Vincent J., et al.
  Pubblicazione: (2021)